“This alliance between Astrazeneca and Daiichi Sankyo is an example of excellent collaboration, because together we share a great sense of responsibility, not only for cancer patients, but for the whole society”. Thus Alessandra Dorigo, head of Oncology of AstraZeneca Italia, on the sidelines of the press conference 'Breast cancer: the new frontiers of treatment', organized in Milan by AstraZeneca and Daiichi Sankyo. At the center of the conference, dedicated to the presentation of new perspectives for the treatment of metastatic breast cancer with low levels of expression of the Her2 receptor, the monoclonal antibody drug conjugate trastuzumab deruxtecan, the reimbursement of which has also been approved by Aifa for this type of patient.
#Breast #cancer #Dorigo #AstraZeneca #Alliance #excellence #Daiichi #Sankyo
